Core - Vector Production

Abstract

The overall function of the Vector Core is to provide high quality retroviral vectors and adeno-associated virus (AAV) vectors to investigatOrs of this SCOR grant. Virtually all of the projects in this SCOR proposal involve utilizing retroviral vectors as an experimental tool to introduce specific genes into hematopoietic stem cells or into different hematopoietic cell lines. The Vector Core will provide different backbone vectors and packaging cell lines as well as appropriate technical advice relating to the most efficient way to engineer high titer vectors for these different studies. The Vector Core will also provide large quantities of retroviral vectors for the baboon studies in Project 6 and will assure that these different vectors are of similar titer. For the human studies proposed in Project 7 the Vector Core will assure production of clinical grade retroviral vectors for use in the gene therapy of leukocyte adherence deficiency (LAD). Quality control assays meeting FDA and RAC requirements including assays for replication-competent virus, adventitious infectious agents, and retroviral genomic rearrangements will largely be carried out in the Vector Core facility or contracted through Microbiological Associates.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Heart, Lung, and Blood Institute (NHLBI)
• Type: Specialized Center (P50)
• Project #: 5P50HL054881-02
• Application #: 2374623
• Budget Start: 1995-10-01
• Budget End: 1996-09-30
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: Fred Hutchinson Cancer Research Center
• DUNS #: 075524595
• City: Seattle
• State: WA
• Country: United States
• Zip Code: 98109

Publications

Varnum-Finney, Barbara; Dallas, Mari H; Kato, Keizo et al. (2008) Notch target Hes5 ensures appropriate Notch induced T- versus B-cell choices in the thymus. Blood 111:2615-20

Piasecki, Julia C; Beagles, Karen; Beard, Brian C et al. (2008) Induction of transgene-specific cytotoxic T lymphocyte responses after transplantation of gene-modified CD34+ cells despite nonablative immunosuppressive conditioning. Hum Gene Ther 19:103-7

Gerull, Sabine; Beard, Brian C; Peterson, Laura J et al. (2007) In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 18:451-6

Jung, Chul Won; Beard, Brian C; Morris, Julia C et al. (2007) Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates. Exp Hematol 35:1132-9

Si, Jutong; Mueller, LeMoyne; Collins, Steven J (2007) CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. J Clin Invest 117:1412-21

Neff, Tobias; Gerull, Sabine; Peterson, Laura J et al. (2007) Improved short-term engraftment of lentivirally versus gammaretrovirally transduced allogeneic canine repopulating cells. J Gene Med 9:357-61

Si, Jutong; Mueller, LeMoyne; Schuler, Aaron et al. (2007) The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. Blood Cells Mol Dis 39:307-15

Aoyama, Keisuke; Delaney, Colleen; Varnum-Finney, Barbara et al. (2007) The interaction of the Wnt and Notch pathways modulates natural killer versus T cell differentiation. Stem Cells 25:2488-97

Dallas, Mari H; Varnum-Finney, Barbara; Martin, Paul J et al. (2007) Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood 109:3579-87

Shepherd, Bryan E; Kiem, Hans-Peter; Lansdorp, Peter M et al. (2007) Hematopoietic stem-cell behavior in nonhuman primates. Blood 110:1806-13